Beata Małachowska1,2,3, Maciej Borowiec4, Karolina Antosik4, Arkadiusz Michalak1, Anna Baranowska-Jaźwiecka1, Grażyna Deja5, Przemysława Jarosz-Chobot5, Agnieszka Brandt6, Małgorzata Myśliwiec6, Małgorzata Stelmach7, Joanna Nazim7, Jadwiga Peczyńska8, Barbara Głowińska-Olszewska9, Anita Horodnicka-Józwa10, Mieczysław Walczak10, Maciej T Małecki11, Agnieszka Zmysłowska1, Agnieszka Szadkowska1, Wojciech Fendler1,2, Wojciech Młynarski1. 1. Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland. 2. Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland. 3. Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland. 4. Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland. 5. Department of Children's Diabetology, Medical School of Silesia, Katowice, Poland. 6. Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Poland. 7. Pediatric Endocrinology Department, University Children's Hospital Jagiellonian University, Medical College, Cracow, Poland. 8. Outpatient Clinic for Pediatric Patients with Diabetes, Bialystok, Poland. 9. Department of Pediatrics, Endocrinology, Diabetology with Cardiology Divisions, Medical University of Bialystok, Bialystok, Poland. 10. Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology of the Developmental Age, Pomeranian Medical University in Szczecin, Szczecin, Poland. 11. Department of Metabolic Disease, Collegium Medicum Jagiellonian University of Cracow, Cracow, Poland.
Abstract
BACKGROUND: Estimated monogenic diabetes (MD) prevalence increases as screening programs proceeds. OBJECTIVE: To estimate prevalence of MD among Polish children. SUBJECTS: Patients and their family members suspected of suffering from MD (defined as causative mutation in one of the Maturity Onset Diabetes of the Young or permanent neonatal diabetes mellitus genes) were recruited between January 2005 and December 2015. METHODS: Nationwide prevalence was estimated based on data from 6 administrative provinces (out of 16 in Poland) with high referral rates of patients (>10 per 100 000 children). RESULTS: During the analysis, probands from 322 of 788 screened families tested positive yielding a total of 409 children and 299 family members with MD. An average of 70 probands/year were referred. Screening success rate reached 40% over the study period. We estimated the prevalence of MD in 2015 to 7.52/100 000 children (1 in 13 000). The most frequent MODY in this group was GCK- MODY (6.88/100 000). The prevalence estimates increased nearly 2-fold since our report in 2011 (4.4/100 000). However, the figure reached a plateau because of screening saturation in 2014 what was also proven by lowering of the median age of diagnosis lowered in time (R = -0.73, P = .0172) along with shortening of the delay between clinical and genetic diagnosis (R = -0.65, P = .0417). CONCLUSIONS: The screening for childhood MD in Poland reached a plateau phase after 10 years showing a stable prevalence estimate. The true frequency of MD in the overall population may be higher given later onset of reportedly more frequent types of MD than GCK -MODY.
BACKGROUND: Estimated monogenic diabetes (MD) prevalence increases as screening programs proceeds. OBJECTIVE: To estimate prevalence of MD among Polish children. SUBJECTS:Patients and their family members suspected of suffering from MD (defined as causative mutation in one of the Maturity Onset Diabetes of the Young or permanent neonatal diabetes mellitus genes) were recruited between January 2005 and December 2015. METHODS: Nationwide prevalence was estimated based on data from 6 administrative provinces (out of 16 in Poland) with high referral rates of patients (>10 per 100 000 children). RESULTS: During the analysis, probands from 322 of 788 screened families tested positive yielding a total of 409 children and 299 family members with MD. An average of 70 probands/year were referred. Screening success rate reached 40% over the study period. We estimated the prevalence of MD in 2015 to 7.52/100 000 children (1 in 13 000). The most frequent MODY in this group was GCK- MODY (6.88/100 000). The prevalence estimates increased nearly 2-fold since our report in 2011 (4.4/100 000). However, the figure reached a plateau because of screening saturation in 2014 what was also proven by lowering of the median age of diagnosis lowered in time (R = -0.73, P = .0172) along with shortening of the delay between clinical and genetic diagnosis (R = -0.65, P = .0417). CONCLUSIONS: The screening for childhood MD in Poland reached a plateau phase after 10 years showing a stable prevalence estimate. The true frequency of MD in the overall population may be higher given later onset of reportedly more frequent types of MD than GCK -MODY.
Authors: Maciej Borowiec; Wojciech Młynarski; Agnieszka Zmyslowska; Marcin Stanczak; Zuzanna Nowicka; Arleta Waszczykowska; Dobromila Baranska; Wojciech Fendler Journal: BMJ Open Diabetes Res Care Date: 2020-11
Authors: Beata Małachowska; Justyna Janikiewicz; Karolina Pietrowska; Krystyna Wyka; Joanna Madzio; Kamila Wypyszczak; Marcin Tkaczyk; Sławomir Chrul; Rafał Zwiech; Anna Hogendorf; Maciej T Małecki; Maciej Borowiec; Adam Krętowski; Wojciech Młynarski; Agnieszka Dobrzyń; Michał Ciborowski; Wojciech Fendler Journal: Metabolomics Date: 2022-02-18 Impact factor: 4.290